高盛发表研报指，石药(01093.HK) 首季业绩表现疲弱，销售额按年下跌22%，成品药销售额下跌27%，相信是由于去年同期基数较高、带量采购及渠道去库存所带来影响，以及恩必普于国家医保目录降价等所拖累。高盛估算，扣除商业开发收入后，石药首季核心盈利按年下跌约45%，不过考虑到管理层专注于提升股东回报，以及今年内或完成三项规模超过50亿美元的产品授权合作交易，预期最坏的时期或已过去。基于业绩及最新...
Source Link高盛发表研报指，石药(01093.HK) 首季业绩表现疲弱，销售额按年下跌22%，成品药销售额下跌27%，相信是由于去年同期基数较高、带量采购及渠道去库存所带来影响，以及恩必普于国家医保目录降价等所拖累。高盛估算，扣除商业开发收入后，石药首季核心盈利按年下跌约45%，不过考虑到管理层专注于提升股东回报，以及今年内或完成三项规模超过50亿美元的产品授权合作交易，预期最坏的时期或已过去。基于业绩及最新...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.